Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

NCT01080209 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Patients Who Participated in an Intravitreal Brimo PS DDS® Study

Interventions

DRUG: Brimo PS DDS®
OTHER: Sham

Sponsor

Allergan